US accuses Russia of using banned chemical weapons in Ukraine
The US Department of State (DoS) accused Moscow on 1 May of breaching the Chemical Weapons Convention (CWC) and conducting gas attacks in Ukraine. The DoS claimed that Russia used riot control agents as a method of warfare and deployed Chloropicrin against Kyiv’s troops.
Also known as PS or nitrochloroform, the choking agent has been banned by the CWC, which the Kremlin joined in 1997. According to the Organisation for the Prohibition of Chemical Weapons (OPCW), Chloropicrin inflicts injury on the respiratory tract and, when inhaled, causes alveoli “to secrete fluid, essentially drowning those affected”.
“The use of such chemicals is not
Already have an account? Log in
Want to keep reading this article?
Read this Article
Get access to this article with a Free Basic Account
- Original curated content, daily across air, land and naval domains
- 2 free stories per week
- Personalised news alerts
- Daily and weekly newsletters
Unlimited Access
Access to all our premium news as a Premium News 365 Member. Corporate subscriptions available.
- Original curated content, daily across air, land and naval domains
- 14-day free trial (cancel at any time)
- Unlimited access to all published premium news
More from Defence Notes
-
How UAE defence giant EDGE Group plans to double its exports
The UAE defence conglomerate has put an aggressive strategy in place to increase its share of exports while navigating the growing gap between East and West.
-
US lawmakers warn that “more military spending is absolutely necessary” to ensure Pentagon’s readiness
The US Congress has raised concerns about how inflation rates and cuts in main acquisition programmes could affect the US military.
-
Can the US overcome Russian and Chinese nuclear capabilities?
Washington’s ageing inventory and the pace Moscow and Beijing have been modernising their capabilities put in check the US Nuclear deterrence.
-
US FY2024 funding package passes as China closes military capability gap
The Pentagon has been operating under temporary funding since October 2023, which has impacted its main acquisition and development programmes, increasing the capability gap between the US and China.